ScripBristol Myers Squibb’s announcement that Camzyos (mavacamten) failed in a Phase III trial in class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) was light on details. But its broader impli
Pink SheetCellares became the first company to announce receipt of an Advanced Manufacturing Technology designation from the US FDA on 1 April 2025, almost three years after the FDA Omnibus Reform Act of 2022 c
ScripScancell has become the second biopharma company – after BioNTech – to join a UK government program designed to accelerate research into personalized cancer vaccines. The Oxford-based firm has announc
ScripBristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimu